Mitsubishi Tanabe Pharma America Presents Real-World Experience Outcomes During IV Edaravone Treatment at Virtual 31st International Symposium on ALS/MND
U.S. Specialty Infusion Provider Data Analysis Shows Consistent Results with Pivotal Phase 3 Study FRISCO, Texas, December 11, 2020 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Soleo Health today announced a virtual poster presentation reviewing the analysis of real-world experience outcomes of treatment with RADICAVA® (edaravone) in people with amyotrophic lateral sclerosis (ALS). The findings were presented as part […]